SciEN MedTech Secures Tens of Millions in Pre-A Funding to Accelerate Commercialization of Cassi Cryo-Biopsy Products and Advance Pipeline Development

Recently, Saien Medical Technology (Lianyungang) Co., Ltd. (hereinafter referred to as “Saien Medical”) announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was led by Tianhui Capital, with Zhoudu Capital serving as the exclusive financial advisor."This round of financing will provide funding and resource support for the commercialization of Saien Medical's first approved cryo-cut biopsy series products, as well as the research and development of innovative therapeutic products in the field of early diagnosis and treatment of tumors."

According to the latest 2020 global cancer burden data released by the World Health Organization, China recorded 4.57 million new cancer cases and 3 million cancer-related deaths in that year, accounting for approximately 30% of the global total. As such, China is one of the countries with the highest cancer burden worldwide.

China’s exceptionally high cancer mortality rate reflects that there is still room for improvement in the country’s cancer treatment technologies. Annual national expenditure on malignant tumors exceeds RMB 220 billion. According to data released by the Actuarial Society of China at the end of December 2020, the average cost of cancer treatment in China ranges from RMB 220,000 to RMB 800,000, ranking among the highest for major diseases. Nevertheless, the five-year survival rate for malignant tumors in China averages only 40.5%, significantly lower than the 68% recorded in the United States during the same period. A core reason for this disparity is that China lags considerably behind developed countries in early diagnosis and early treatment of tumors. The population covered by early cancer screening and intervention in China is relatively small, and public awareness and initiative in undergoing preventive cancer check-ups remain insufficient. As a result, most patients are diagnosed at intermediate or advanced stages, which adversely affects treatment outcomes. Taking liver cancer as an example, patients at Stage III and IV account for 55% of all diagnosed cases in China, compared with only 15% in the United States and 5% in Japan during the same period—representing gaps of fourfold and elevenfold, respectively. To improve cancer survival rates, prevention along with early diagnosis and early treatment is critical. The cure rate for early-stage cancers can exceed 90%. During the “Two Sessions,” it was explicitly proposed that cancer prevention and control strategies should be shifted upstream, making precise early diagnosis and treatment one of the most effective approaches to improving cancer cure rates. This approach would also substantially reduce medical insurance expenditures and enhance patients’ quality of life.

Saien Medical is dedicated to building a platform for the early diagnosis and treatment of cancer. With a global market focus, the company provides integrated solutions centered on scenarios for early cancer detection and management. Its first series of cryo-core biopsy products has received regulatory approval for market launch and has been highly acclaimed by clinical experts. Despite being a startup, Saien Medical has already achieved commercial self-sufficiency, rapidly completing tendering, online listing, market access, and sales processes within less than a year, thereby offering clinicians better product choices.

The company’s rapid growth is attributable to its founding team, which boasts extensive industry experience and keen business acumen. Founder Li Chenguang brings over 20 years of experience across the entire medical device industry chain, with exceptional expertise in strategy, marketing, commercialization, and M&A integration. As a serial entrepreneur with multiple successful ventures, he places strong emphasis on application scenarios and unmet clinical needs when structuring the product pipeline. In a relatively short period, Mr. Li has successfully led his team in achieving end-to-end technology translation from concept to market, driving commercialization and expanding overseas, thereby laying a solid foundation for the company’s future development.

A diversified business layout is one of the company’s core strategies. The company’s first product, the cryo-core biopsy needle, has successfully achieved commercialization. To date, it has been listed for procurement access in nearly 20 provinces and municipalities and is being sold in more than 30 hospitals. This product’s innovative technology addresses critical clinical pain points. Its unique pneumatic core-cutting design effectively enhances stability, while the cryotechnology helps freeze and immobilize lesions, preventing tissue displacement and significantly improving sample integrity. Compared with conventional needles, it reduces operational difficulty and substantially lowers the false-negative rate, making it one of the most precise products currently available. It fills the gap in high-end biopsy methods for solid tumors, promoting greater precision and safety in procedural practices. The product has demonstrated strong advantages in biopsies of the thyroid, lungs, axillary lymph nodes, breast, and other tissues, earning consistent acclaim from experts at leading Grade A tertiary hospitals.

The company has made in-depth strategic investments in precision diagnosis and treatment scenarios for early-stage tumors. Its future product pipeline aims to develop efficient and comprehensive solutions, providing clinicians with a broader range of superior product options.

In the current capital market environment, Saien Medical’s ability to rapidly complete a Pre-A financing round worth tens of millions of yuan within three months is attributable to its founding team’s deep cultivation and precise understanding of the oncology market. By adhering to the principle of “high-quality products + unmet clinical needs + multi-scenario applications,” the company has continuously identified genuine clinical pain points and advanced the clinical application of its products with an end-goal-oriented approach, thereby earning recognition from professional investors.

Li Chenguang, founder of Saien Medical, stated:We sincerely appreciate Tianhui Capital’s recognition of the company’s entrepreneurial achievements over the past four years. The company’s current product line—the Cassi Cryobiopsy Series—has garnered high acclaim from clinical experts and the market, providing a solid foundation for a startup. Moving forward, the company will continue to focus on the oncology sector, collaborating with clinical experts and academic research institutions to refine its product pipeline. We remain committed to developing innovative, marketable products that meet clinical needs. Additionally, the company will recruit more professional talent, upholding our corporate culture of “embracing responsibility, prioritizing execution, achieving excellence through attention to detail, and valuing efficiency above all,” as we strive together to achieve our next set of established goals.

Deng Jianliang, Partner at Tianhui Capital, stated:Tianhui Capital fully recognizes the pioneering spirit and strong execution capabilities of the founding team led by Li Chenguang. Leveraging the founding team’s extensive experience at renowned multinational medical device companies, as well as their profound understanding of the domestic medical device market and unmet clinical needs, Saien Medical has, within a relatively short period, achieved regulatory approval, hospital adoption, and commercial sales of its Cassi cryobiopsy product in the Chinese market, earning widespread recognition from clinical experts and the market alike. It is expected that, with the continuous enhancement of the company’s R&D capabilities and deepening collaboration with external research institutions, Saien Medical will further enrich and refine its product pipeline around integrated solutions for the early diagnosis and treatment of tumors, thereby benefiting more patients with tumors and nodules.

Tianhui Capital will also leverage its deep expertise and understanding of the healthcare sector, relying on its established “Fund + Alliance + Ecosystem Chain” investment management model, to provide professional post-investment value-added services to Saien Medical in areas such as corporate development strategy, R&D project initiation, upstream and downstream supply chain collaboration, market resource introduction, team incentives, and follow-on financing, thereby accelerating Saien Medical’s rapid growth.

Zhoudu Capital stated:We are honored to have served as the exclusive financial advisor to the company in facilitating this round of financing. Amidst the current challenging environment, Saien Medical has demonstrated remarkable resilience and exceptional execution capabilities. By deeply exploring scenarios for early diagnosis and treatment of cancer, the company has earned consistent recognition from clinical experts. Cancer remains a critical and notoriously difficult disease to cure; earlier and more precise detection and treatment can significantly improve cure rates and quality of life. The founder possesses extensive management experience in multinational corporations and a track record of successful serial entrepreneurship, complemented by keen business acumen. Under his leadership, the team has achieved efficient product development, secured listing on provincial procurement platforms, and established a closed-loop sales network across dozens of hospitals. The product has demonstrated significant differentiated positioning in clinical practice, unlocking numerous application scenarios. We are highly optimistic about the company’s growth trajectory and believe that, with its solid fundamentals and the support of capital, Saien Medical is poised to become a leading enterprise in cancer treatment during this new phase of corporate development.

Tianhui Capital (i.e., Tianhui Hongyou & Tianhui Sumitomo) is a value investor, integrator, and navigator deeply rooted in the healthcare industry, and has gradually expanded its investment layout into emerging industries such as new materials, new energy, and intelligent manufacturing.

The company’s core team has nearly 23 years of experience in equity investment management. It adopts an investment management model of “Fund + Alliance + Ecosystem Chain,” formulates a “Four-Pronged” investment strategy characterized by “Specialization, Early-Stage Focus, Platformization, and Internationalization,” and systematically constructs a post-investment management system based on the “1+1+N” framework, the “3+3” model, and the “100-Day Navigation Assistance” program. This approach accelerates the development of the core businesses of portfolio companies while actively promoting the growth of related emerging industries.

Some typical cases of the company and its team include: Simcere Pharmaceutical (02096.HK), Jinhe Industrial (002597.SZ), Nanomicro Tech (688690.SH), Dian Diagnostics (300244.SZ), AIM Vaccine (06660.HK)/Livanda, Anhui Wanbang Pharma, Baiying Biotech, Tnuo Mab, Xankai Biotech, Geneseeq, Magigene, Nuoyuan Medical, Hanhai New Enzyme, Luoqi Biologics, Huijian Technology, Baisai Biotech, WeLion New Energy, Si'airan, Anchun Technology, Saien Medical, etc.